TY - JOUR
T1 - Predominance of a drifted influenza a (H3N2) clade and its association with age-specific influenza vaccine effectiveness variations, influenza season 2018–2019
AU - Glatman-Freedman, Aharona
AU - Pando, Rakefet
AU - Sefty, Hanna
AU - Omer, Itay
AU - Rosenberg, Alina
AU - Drori, Yaron
AU - Nemet, Ital
AU - Mendelson, Ella
AU - Keinan-Boker, Lital
AU - Mandelboim, Michal
N1 - Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. T.
PY - 2020/2/9
Y1 - 2020/2/9
N2 - Background: Influenza A (H3N2) clade 3C.3a was the predominant influenza virus in Israel throughout the 2018-2019 season, constituting a drift from the influenza A (H3N2) vaccine. We estimated the end-of season vaccine effectiveness (VE) by age, among community patients with influenza-like illness (ILI), considering the hemagglutinin (HA) gene mutations and amino acid substitutions of influenza A (H3N2) viruses detected. Methods: Nose-throat samples were analyzed for the presence of influenza virus, type/subtype, and HA gene sequence. HA gene sequences and amino acid substitutions were compared to the influenza A/Singapore/INFIMH-16-0019/2016 (H3N2)-like 2018-2019 vaccine virus, and a phylogenetic tree was generated. Influenza VE against influenza A (H3N2) was estimated using the test-negative design. VE was estimated by age group and by 15 year moving age intervals. Results: In total, 90% of the influenza A (H3N2) viruses belonged to the 3C.3a clade, constituting a unique situation in the northern hemisphere. Adjusted all-age influenza A (H3N2) VE was −3.5% (95% CI: −51.2 to 29.1). Although adjusted VEs were very low among infants, children, and young adults, a VE of 45% (95% CI: −19.2 to 74.6) was estimated among adults aged ≥45 years old. Conclusions: The higher VE point estimates among older adults may be related to previous exposure to similar influenza viruses.
AB - Background: Influenza A (H3N2) clade 3C.3a was the predominant influenza virus in Israel throughout the 2018-2019 season, constituting a drift from the influenza A (H3N2) vaccine. We estimated the end-of season vaccine effectiveness (VE) by age, among community patients with influenza-like illness (ILI), considering the hemagglutinin (HA) gene mutations and amino acid substitutions of influenza A (H3N2) viruses detected. Methods: Nose-throat samples were analyzed for the presence of influenza virus, type/subtype, and HA gene sequence. HA gene sequences and amino acid substitutions were compared to the influenza A/Singapore/INFIMH-16-0019/2016 (H3N2)-like 2018-2019 vaccine virus, and a phylogenetic tree was generated. Influenza VE against influenza A (H3N2) was estimated using the test-negative design. VE was estimated by age group and by 15 year moving age intervals. Results: In total, 90% of the influenza A (H3N2) viruses belonged to the 3C.3a clade, constituting a unique situation in the northern hemisphere. Adjusted all-age influenza A (H3N2) VE was −3.5% (95% CI: −51.2 to 29.1). Although adjusted VEs were very low among infants, children, and young adults, a VE of 45% (95% CI: −19.2 to 74.6) was estimated among adults aged ≥45 years old. Conclusions: The higher VE point estimates among older adults may be related to previous exposure to similar influenza viruses.
KW - Drift
KW - Influenza A (H3N2)
KW - Influenza vaccine
KW - Vaccine effectiveness
UR - http://www.scopus.com/inward/record.url?scp=85079447955&partnerID=8YFLogxK
U2 - https://doi.org/10.3390/vaccines8010078
DO - https://doi.org/10.3390/vaccines8010078
M3 - Article
C2 - 32050460
SN - 2076-393X
VL - 8
JO - Vaccines
JF - Vaccines
IS - 1
M1 - 78
ER -